Residents invited to take part in liver testing
Residents in Stoke-on-Trent are being invited to take part in free liver testing at two local roadshows funded by a doctor who died from cancer.
Dr Alison Brind, 63, who specialised in liver disease, worked with patients in Stoke-on-Trent and Staffordshire for more than 25 years.
The consultant gastroenterologist, who worked at University Hospitals of North Midlands (UHNM), was diagnosed with pancreatic cancer in 2022 and died in April last year.
After identifying people at risk of liver disease at roadshows in 2023, Dr Brind, who raised more than £10,000 for the UHNM charity, decided to fund the scheme for another five years, organisers said previously.
Two Love Your Liver roadshows are being held at Stoke City's Bet365 Stadium on Tuesday and at Port Vale Football Club on Wednesday between 10:00 and 16:00 BST.
Vanessa Carr, liver clinical nurse specialist, said visitors would be offered a free liver health scan and could also speak to a dedicated liver health team for advice and support.
"One in 10 adults in Stoke-on-Trent may have liver disease but be completely unaware because there are usually no symptoms in the early stages," she said.
"But the earlier the disease is detected, the better chance there is to reduce and then reverse any damage."
Ms Carr said liver disease remained one of the leading causes of premature death in the area.
"None of this would have been possible without Dr Alison Brind who has been an absolute inspiration to us over the past 25 years and we continue to work in her memory," she said.
Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram.
'Truly inspirational' doctor and fundraiser dies
Doctor with cancer 'honoured' by work award
'I want to be remembered for liver disease work'
UHNM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Women issued safety warning over period tracker apps
Experts have warned that women using period tracker apps face "real and frightening privacy and safety risks." Academics from the University of Cambridge have said that personal information within the app can be collected and "sold at scale." A new report from the Minderoo Centre for Technology and Democracy at Cambridge stated that this poses risks and harms for users. Researchers have said that menstrual data can provide insights into people's health and their reproductive choices. The apps can collect information on exercise, diet, medication, sexual preferences, hormone levels, and contraception use. The authors of the report added that this information can be a "gold mine" for consumer profiling. Many women who download the apps do so when they are trying to get pregnant, which the authors point out leads to a dramatic shift in shopping behaviour. 'Data on who is pregnant, and who wants to be, has therefore emerged as some of the most sought-after information in digital advertising,' they said. The point out how period tracking apps have rapidly risen in popularity, with global downloads of the three most popular apps surpassing 250 million. 'Cycle tracking apps (CTA) are a lucrative business because they provide the companies behind the apps with access to extremely valuable and fine-grained user data,' the experts wrote in their new report. 'CTA data is not only commercially valuable and shared with an inextricable net if third parties (thereby making intimate user information exploitable for targeted advertising), but it also poses severe security risks for users.' They point out that in the wrong hands, the data collected by the apps could result in health insurance 'discrimination'; risks to job prospects or even domestic abuse. The research team called for better governance of the 'femtech' industry, including improved data security of these apps and for them to introduce 'meaningful consent options'. They also called for public health bodies to launch alternatives to commercial tracking apps. 'Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,' said Dr Stefanie Felsberger, lead author of the report. 'Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.' 'There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.' Professor Gina Neff, executive director of Cambridge's Minderoo Centre, added: 'The use of cycle tracking apps is at an all-time high. 'Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.'
Yahoo
3 hours ago
- Yahoo
Experts warn of risks linked to period tracker apps
Women face 'real and frightening privacy and safety risks' when using period tracker apps, experts have warned. Academics from the University of Cambridge said that personal information in the app can be collected and 'sold at scale'. A new report from experts at Cambridge's Minderoo Centre for Technology and Democracy said that this 'poses risks and harms for users'. Researchers said that menstrual data can provide insights into people's health and their reproductive choices. These apps can collect information on exercise, diet, medication, sexual preferences, hormone levels and contraception use, they added. This information can be a 'gold mine' for consumer profiling, the authors of the new report said. Many women who download the apps do so when they are trying to get pregnant, which the authors point out leads to a dramatic shift in shopping behaviour. 'Data on who is pregnant, and who wants to be, has therefore emerged as some of the most sought-after information in digital advertising,' they said. The point out how period tracking apps have rapidly risen in popularity, with global downloads of the three most popular apps surpassing 250 million. 'Cycle tracking apps (CTA) are a lucrative business because they provide the companies behind the apps with access to extremely valuable and fine-grained user data,' the experts wrote in their new report. 'CTA data is not only commercially valuable and shared with an inextricable net if third parties (thereby making intimate user information exploitable for targeted advertising), but it also poses severe security risks for users.' They point out that in the wrong hands, the data collected by the apps could result in health insurance 'discrimination'; risks to job prospects or even domestic abuse. The research team called for better governance of the 'femtech' industry, including improved data security of these apps and for them to introduce 'meaningful consent options'. They also called for public health bodies to launch alternatives to commercial tracking apps. 'Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,' said Dr Stefanie Felsberger, lead author of the report. 'Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.' 'There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.' Professor Gina Neff, executive director of Cambridge's Minderoo Centre, added: 'The use of cycle tracking apps is at an all-time high. 'Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Scientists find new pathway which could help prevent diet-related liver cancer
Researchers have discovered a scientific pathway that could prevent fatty liver disease, caused by a Western diet high in fat and sugar, from progressing to liver cancer. Scientists said that cases of the cancer arising from underlying fatty liver disease are on the rise. However currently there are said to be no effective therapies to stop fatty liver disease from progressing to liver cancer due to a lack of understanding of the mechanisms involved. Glasgow Caledonian University cancer experts along with scientists from the Cancer Research UK Scotland Institute and The Francis Crick Institute previously identified the tumour suppressor gene p53 as crucial in protecting the liver against toxins. They have now discovered that p53 also protects the liver from the damaging effects of a high-fat, high-sugar diet. Scientists found that it does so through a gene known as TIGAR, which acts as an antioxidant and detoxifies lipids in a fatty liver. Experts said the breakthrough suggests antioxidant therapy could be developed to mimic the protective response of p53 and TIGAR, which would prevent the development of some of the key features of fatty liver disease. Dr Timothy Humpton, who leads the 'Liver p53 lab' at Glasgow Caledonian University, worked on the research paper with his PhD student Celine Wittke, who is co-first author with Dr Eric Cheung, from The Francis Crick Institute. Dr Humpton said: 'This research has established a key role for p53 and TIGAR in protecting against the progression from liver disease to liver cancer. Targeting this through the use of antioxidants is of great interest for future therapies aiming to prevent liver cancer. 'Many people still don't realise that a bad diet full of fat and sugar, and the lack of exercise, can actually cause fatty liver disease which can progress to liver cancer, so it's not just people who drink alcohol that are susceptible.' 'Fatty liver disease is hard to diagnose because it's asymptomatic for the most part. 'That's why liver cancer prognosis is so poor in these patients. It's frequently not flagged until it's advanced cancer. 'We are hoping that an antioxidant therapy can be developed through the results of our p53 and TIGAR research to help reverse some of the damage done to the liver by the Western diet high in fat and sugar.' The research is published in JHep Reports, a leading journal in the field of Gastroenterology and Hepatology.
